Doximity price target lowered to $20 from $25 at BMO Capital

BMO Capital analyst Sean Dodge lowered the firm’s price target on Doximity (DOCS) to $20 from $25 and keeps a Market Perform rating on the shares. The company’s Q4 results beat-revenue and EBITDA, though investors will primarily be focused on the initial FY27 guidance, which was well below expectations as a result of persistent macro headwinds and elevated “AI Investment Year”-related costs., the analyst tells investors in a research note. BMO adds it remains on the sidelines given the low near-term macro visibility and path to AI commercialization.